809 related articles for article (PubMed ID: 33159047)
21. Proteomic and genetic approaches identify Syk as an AML target.
Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
[TBL] [Abstract][Full Text] [Related]
22. Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.
Sadovnik I; Hoelbl-Kovacic A; Herrmann H; Eisenwort G; Cerny-Reiterer S; Warsch W; Hoermann G; Greiner G; Blatt K; Peter B; Stefanzl G; Berger D; Bilban M; Herndlhofer S; Sill H; Sperr WR; Streubel B; Mannhalter C; Holyoake TL; Sexl V; Valent P
Clin Cancer Res; 2016 Apr; 22(8):2051-61. PubMed ID: 26607600
[TBL] [Abstract][Full Text] [Related]
23. CD82 regulates STAT5/IL-10 and supports survival of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
Int J Cancer; 2014 Jan; 134(1):55-64. PubMed ID: 23797738
[TBL] [Abstract][Full Text] [Related]
24. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
25. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
26. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib suppresses acute myelogenous leukaemia stem-like KG-1a cells via NF-κB inhibition and the induction of oxidative stress.
Costa RGA; Oliveira MS; Rodrigues ACBDC; Silva SLR; Dias IRSB; Soares MBP; de Faro Valverde L; Gurgel Rocha CA; Dias RB; Bezerra DP
J Cell Mol Med; 2024 Apr; 28(8):e18333. PubMed ID: 38652192
[TBL] [Abstract][Full Text] [Related]
28. Live kinase B1 maintains CD34
Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
[TBL] [Abstract][Full Text] [Related]
29. MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia.
Liu B; Ma H; Liu Q; Xiao Y; Pan S; Zhou H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):200. PubMed ID: 31097000
[TBL] [Abstract][Full Text] [Related]
30. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
[TBL] [Abstract][Full Text] [Related]
31. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
32. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia.
Eisenwort G; Sadovnik I; Keller A; Ivanov D; Peter B; Berger D; Stefanzl G; Bauer K; Slavnitsch K; Greiner G; Gleixner KV; Sperr WR; Willmann M; Sill H; Bettelheim P; Geissler K; Deininger M; Rülicke T; Valent P
Leukemia; 2021 Nov; 35(11):3176-3187. PubMed ID: 33785864
[TBL] [Abstract][Full Text] [Related]
34. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
Herrmann H; Blatt K; Shi J; Gleixner KV; Cerny-Reiterer S; Müllauer L; Vakoc CR; Sperr WR; Horny HP; Bradner JE; Zuber J; Valent P
Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
[TBL] [Abstract][Full Text] [Related]
35. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
36. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
37. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
38. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
39. Spleen tyrosine kinase mediates the actions of EPO and GM-CSF and coordinates with TGF-β in erythropoiesis.
Chang HC; Huang DY; Wu MS; Chu CL; Tzeng SJ; Lin WW
Biochim Biophys Acta Mol Cell Res; 2017 Apr; 1864(4):687-696. PubMed ID: 28131718
[TBL] [Abstract][Full Text] [Related]
40. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
